AzTrials
AzTrials

Differentiated Thyroid Gland CarcinomaNCT07529080

Personalized Cancer Support (Thrive Track) to Manage the Emotional Needs of Young Adults With Thyroid, Melanoma and Testicular Cancer, PerCS-YA Trial

A study testing Internet-Based Intervention, Interview and Questionnaire Administration in people with Differentiated Thyroid Gland Carcinoma and Malignant Testicular Neoplasm, run by University of Michigan Rogel Cancer Center at 1 site in United States.

Not yet recruiting

Opening soon. The study is approved but enrolment has not started yet. Sites may already take enquiries.

Sites and contacts
Official record
Search all trials

Trial summary

This pilot clinical trial is intended to compare the effect of a psychosocial support tool for young adult (YA)cancer survivors - including high-quality information about their cancer combined with evidence-based psychosocial support - to a support tool providing cancer-specific information alone (minus psychosocial… Read more about this study

Who is it for?
Ages 20 to 39 years
What is being tested?
Internet-Based Intervention, Interview and Questionnaire Administration
Could I receive a placebo?
No, everyone receives an active treatment
How many people
142 participants
Where
1 siteUnited States
Study dates
Dec 2026to Dec 2027
Phase
Interventional
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 20 to 39 years
  • All sexes
  • No healthy volunteers
  • Adult

Who may be able to join

  • PARTICIPANTS RECRUITED FROM SURVEILLANCE, EPIDEMIOLOGY, AND END RESULTS PROGRAM (SEER)-GEORGIA: Age 18-37 at time of cancer diagnosis and age 20-39 at time of enrollment
  • PARTICIPANTS RECRUITED FROM SEER-GEORGIA: Diagnosed with differentiated thyroid cancer (papillary or follicular thyroid cancer), melanoma, or testicular cancer at any stage and reported to the SEER-Georgia registry
  • PARTICIPANTS RECRUITED FROM SEER-GEORGIA: 2-10 years after diagnosis with cancer
  • PARTICIPANTS RECRUITED FROM SEER-GEORGIA: English speaking (able to read and speak English)
  • PARTICIPANTS RECRUITED FROM SEER-GEORGIA: Report of any cancer-related worry (on a 5-point Likert scale from not at all to very worried; those who indicate "not at all" will be told the study is focused on those who experience worry)
  • PARTICIPANTS RECRUITED FROM SEER-GEORGIA: Residing in the United States
Show all 12Show fewer
  • PARTICIPANTS RECRUITED FROM THYROID CANCER SURVIVORS' ASSOCIATION INC. (THYCA): Age 18-37 at time of cancer diagnosis and age 20-39 at time of enrollment
  • PARTICIPANTS RECRUITED FROM THYCA: Diagnosed with differentiated thyroid cancer (papillary or follicular thyroid cancer) at any stage
  • PARTICIPANTS RECRUITED FROM THYCA: 2-10 years after diagnosis with cancer
  • PARTICIPANTS RECRUITED FROM THYCA: English speaking (able to read and speak English)
  • PARTICIPANTS RECRUITED FROM THYCA: Report of any cancer-related worry (on a 5-point Likert scale from not at all to very worried; those who indicate "not at all" will be told the study is focused on those who experience worry)
  • PARTICIPANTS RECRUITED FROM THYCA: Residing in the United States

Who cannot join

  • PARTICIPANTS RECRUITED FROM SEER-GEORGIA: Subjects from certain vulnerable populations will be excluded as appropriate: fetuses, neonates, children under age 18, prisoners, institutionalized individuals, or others who may be considered vulnerable populations per the National Institutes of Health (NIH) and Office for Human Research Protections (OHRP)
  • It is possible that a subject might be pregnant. Because this involves surveys and reviewing an informational website, participation should have no additional risk for a pregnant woman
  • PARTICIPANTS RECRUITED FROM SEER-GEORGIA: Subjects that do not meet the inclusion criteria
  • PARTICIPANTS RECRUITED FROM THYCA: Subjects from certain vulnerable populations will be excluded as appropriate fetuses, neonates, children under age 18, prisoners, institutionalized individuals, or others who may be considered vulnerable populations per the National Institutes of Health (NIH) and Office for Human Research Protections (OHRP)
  • It is possible that a subject might be pregnant. Because this involves surveys and reviewing an informational website, participation should have no additional risk for a pregnant woman
  • PARTICIPANTS RECRUITED FROM THYCA: Subjects that do not meet the inclusion criteria

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

Megan Haymart, MD contact

734-615-6745

support@thrivetrack.study

United States1 site

  • University of Michigan Rogel Cancer Center

    Ann Arbor, Michigan, 48109

    Megan R. Haymart, MD, 734-615-6745, support@thrivetrack.study

    Megan R. Haymart, MD

Other trials in United States

About this study

Official title: Personalized Cancer Support for Young Adults

This pilot clinical trial is intended to compare the effect of a psychosocial support tool for young adult (YA)cancer survivors - including high-quality information about their cancer combined with evidence-based psychosocial support - to a support tool providing cancer-specific information alone (minus psychosocial modules). This tool, called Thrive Track, will be for YA patients aged 20-39 with thyroid, melanoma, or testicular cancer. Young adult survivors frequently experience persistent worry and distress that can interfere with coping and reduce quality of life. They are also particularly vulnerable to the emotional impact of cancer and may not have adequate support to manage these concerns. The enhanced version of Thrive Track includes personalized emotional support content and strategies designed to help patients better manage worry and distress. Adding these emotional support tools may provide greater benefit than survivorship education alone in strengthening young adult survivors' ability to manage their emotional well-being.

Being tested
Internet-Based Intervention, Interview, Questionnaire Administration
Medical subject headings
Testicular Neoplasms, Melanoma, Adenocarcinoma, Follicular, Thyroid Cancer, Papillary

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Internet-Based InterventionOther

    Receive access to Thrive Track website with general cancer-specific survivorship care information

  • Internet-Based InterventionOther

    Receive access to Thrive Track website with general cancer-specific survivorship care information in addition to emotional support content

  • InterviewOther

    Ancillary studies

  • Questionnaire AdministrationOther

    Ancillary studies

Study groups in NCT07529080
Study groupRoleWhat they receive
Arm I (Thrive control)Active comparatorPatients receive access to Thrive Track website with general cancer-specific survivorship care information for up to 3 months.
Receives: Other: Internet-Based Intervention; Other: Interview; Other: Questionnaire Administration
Arm II (Thrive Track with emotional support)ExperimentalPatients receive access to Thrive Track website with general cancer-specific survivorship care information in addition to emotional support content for up to 3 months.
Receives: Other: Internet-Based Intervention; Other: Interview; Other: Questionnaire Administration

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Cancer related worry

    Cancer-related worry will be evaluated using two 8-item validated scales:

    1. Cancer Worry Scale (CWS)
    2. An adapted cancer worry scale

    Overall as well as stratified analyses (by recruitment source and cancer type) will be performed. We will compare mean scores on the two scales between intervention and control subjects at 3 months post intervention. Scores on the CWS scale range from 8 (minimum) to 32 (maximum), with lower scores indicating less cancer-related worry and more favorable outcomes.

    Scores on the adapted cancer worry scale range from 8 (minimum) to 40 (maximum), with lower scores indicating less cancer-related worry and more favorable outcomes.

    Measured: 3 months post-enrollment

  2. Cancer related distress

    Cancer-related distress will be measured using the National Comprehensive Cancer Network Distress Thermometer.

    Scores on the NCCN Distress Thermometer range from 0 (minimum) to 10 (maximum), with lower scores indicating less distress and more favorable outcomes.

    Overall as well as stratified analyses (by recruitment source and cancer type) will be performed. We will compare mean scores on the distress thermometer between the intervention and control subjects at 3 months post-intervention using two-sample t-tests.

    Measured: 3 months post-enrollment

Secondary outcomes (4)

  1. Knowledge about worry self-management

    This outcome will be evaluated using a team-developed 4-item scale. Scores on this scale range from 4 (minimum) to 16 (maximum), with higher scores indicating better knowledge about how to self-manage worry and more favorable outcomes.

    Measured: 3 months post-enrollment

  2. Confidence/self-efficacy in the ability to self-manage worry

    This outcome will be evaluated using an 11-item scale from the Breast Cancer Self Efficacy Scale (BCSE), adapted for all cancers.

    Scores on this scale range from 11 (minimum) to 55 (maximum), with higher scores indicating better self efficacy to manage cancer-related worry and more favorable outcomes.

    Measured: At 3 months post-enrollment

  3. Resilience

    This outcome will be evaluated using a 6-item validated scale, adapted from the Communication and Attitudinal Self-Efficacy Scale (CASE) and the Cancer Control and Outlook Scale.

    Scores on this scale range from 6 (minimum) to 30 (maximum), with higher scores indicating better resilience to deal with cancer and more favorable outcomes.

    Measured: At 3 months post-enrollment

  4. Ease of tool use

    This outcome will be evaluated using a series of 7 questions designed to help understand the participants' experience using the Thrive Track website.

    Measured: At 3 months post-enrollment

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted14 Apr 2026
  2. Study startDec 2026 (estimated)
  3. Primary completionDec 2027 (estimated)
  4. Study completionDec 2027 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Supportive care
Allocation
Randomised
Intervention model
Parallel groups
Masking
Single blind
Who is masked
Participant
Enrolment
142 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07529080
Sponsor's protocol ID
UMCC 2025.051
Other IDs
NCI-2026-00929, HUM00270736, R34CA286602
Status last verified
Oct 2026
First submitted
5 Mar 2026
Last updated
15 Oct 2026
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Yes: As described in our Data Management and Sharing plan (DMS), all the final data generated from this study will be de-identified and uploaded to the Inter-University Consortium for Political and Social Research (ICPSR). Additionally, the primary outcome results of the study will be reported to ClinicalTrials.gov no later than 1 year after the primary completion date of the trial.

Questions about this trial

What is this clinical trial studying?

A study testing Internet-Based Intervention, Interview and Questionnaire Administration in people with Differentiated Thyroid Gland Carcinoma and Malignant Testicular Neoplasm, run by University of Michigan Rogel Cancer Center at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 12 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: opening soon, as of the sponsor's last update on 15 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Megan Haymart, MD (734-615-6745, support@thrivetrack.study), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Cancer related worry (time frame: 3 months post-enrollment). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT07529080.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 15 Oct 2026.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in